“Becker Muscular Dystrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Becker Muscular ...
– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Treatment with EDG-5506 resulted in significant ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present on EDG-5506, an orally ...
The drug tadalafil (Cialis, Lilly), already approved to treat erectile dysfunction and pulmonary hypertension, also corrects abnormal blood flow in exercised forearms of men with Becker muscular ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback